pSivida (PSDV) announced that the Transparency Commission of the French National Health Authority has issued a favorable opinion for the reimbursement and hospital listing by the French National Health Insurance of ILUVIEN for the treatment of chronic diabetic macular edema considered insufficiently responsive to available therapies and despite optimized management of diabetes. ILUVIEN is licensed to and sold by Alimera Sciences (ALIM). In France, patients will be reimbursed for 100% of the cost of ILUVIEN under Affection de Longue Duree. Alimera has reported that it will now move forward to determine the price and any reimbursement conditions for ILUVIEN in France with the Comite Economique des Produits de Sante or CEPS. Alimera further reported that it believes the CT’s positive opinion for reimbursement of ILUVIEN will help it in its discussions with the CEPS pricing committee.